CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
Virtual Screening & Data Scientist (m/f/d)
Bionorica research GmbH, situated Innsbruck, is an Austrian subsidiary of Bionorica SE (Neumarkt, Germany). Bionorica SE has 1800 employees worldwide and is German market leader for herbal medicine produc...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
